Abstracts tagged "cytokines and inflammation"

Abstract Number: 1029 • 2019 ACR/ARP Annual Meeting
Epstein-Barr Virus Interleukin 10 in SLE Pathogenesis
Neelakshi R. Jog¹, Wade DeJager ¹, Joel Guthridge ² and Judith James ², ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease characterized by periods of elevated and suppressed disease activity. Epstein Barr Virus (EBV) has been…
Abstract Number: 62 • 2018 ACR/ARHP Annual Meeting
CCR6+CD4+ T Cells Drive IL-23R Signaling-Dependent Progression of Antigen-Induced Arthritis
W Razawy¹, N Salioska², P Asmawidjaja³, A Otten-Mus⁴, N Kops⁵, M Oukka⁶, V Kuchroo⁷ and Erik Lubberts³, ¹Rheumatology and Immunology, Erasmus MC, Rotterdam, Netherlands, ²Rheumatology, Erasmus MC, Rotterdam, Netherlands, ³Rheumatology and Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁴Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁵Orthopedics, Erasmus MC, Rotterdam, Netherlands, ⁶Pediatrics, Seattle Children's Research Institute, Seattle, WA, ⁷Center for Neurologic Diseases, Harvard Institute of Medicine, Boston, MA
Background/Purpose: The IL-23/IL-17A immune pathway is important for the progression of T cell-mediated arthritis. However, it is not known where IL-23R+ T cells locate during…
Abstract Number: 904 • 2015 ACR/ARHP Annual Meeting
Intracerebroventricular Tweak (TNF-like weak inducer of apoptosis) Induces Depressive-like Behavior and Cognitive Dysfunction in Non-Autoimmune Mice
Jing Wen¹, Christopher Chen¹, Ariel Stock¹, Jessica Doerner¹, Maria Gulinello¹ and Chaim Putterman^1,2, ¹Albert Einstein College of Medicine, Bronx, NY, ²Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Neuropsychiatric lupus (NPSLE) is a common disease manifestation in lupus patients; however, the underlying mechanisms are not fully understood. TWEAK is a cytokine member…
Abstract Number: 1775 • 2015 ACR/ARHP Annual Meeting
Fn14 Deficiency Protects Lupus-Prone Mice from Cutaneous Lesions Induced By Ultraviolet B (UVB) Irradiation
Jessica Doerner¹, Adam Friedman², Linda Burkly³ and Chaim Putterman⁴, ¹Albert Einstein College of Medicine, Bronx, NY, ²Department of Dermatology, George Washington School of Medicine and Health Sciences, Washington, DC, ³Biogen Idec, Cambridge, MA, ⁴The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Sunlight, via ultraviolet B (UVB) irradiation, is a well-recognized trigger of cutaneous lupus erythematosus (CLE) skin lesions. TNF-like weak inducer of apoptosis (TWEAK), a…
Abstract Number: 1856 • 2015 ACR/ARHP Annual Meeting
Exosomes from Patients with Active Systemic Lupus Erythematosus Induce a Strong Inflammatory Response
Joo Youn Lee¹, Jin Kyun Park^1,2, Eun Young Lee³, Eun Bong Lee³ and Yeong Wook Song^1,2, ¹Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine Seoul National University, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
Background/Purpose: Exosomes are 60–150 nm membrane vesicles that are secreted by various cells into surrounding body fluids including blood and urine. As vehicles for intercellular…
Abstract Number: 724 • 2013 ACR/ARHP Annual Meeting
Dose-Dependent Suppression Of Cytokine Production From T Cells By a Novel Phosphoinositide 3-Kinase Delta Inhibitor
Emily E. Way¹, Kong Chen², Kamal D. Puri³ and Jay K. Kolls², ¹Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ²Richard King Mellon Foundation Institute for Pediatric Research, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ³Gilead Sciences, Inc., Seattle, WA
Background/Purpose: The use of specific cytokine inhibitors to treat inflammatory autoimmune conditions is common but typically utilizes monoclonal antibodies, fusion proteins, and other molecules whose…
Abstract Number: 2222 • 2013 ACR/ARHP Annual Meeting
Positive Allosteric Modulation Of The Adenosine A_2a Receptor Alters Inflammatory Cytokine Production and Alleviates Chronic Arthritis In Rats
Ajith A. Welihinda, Jordan A. Mechanic and Edward P. Amento, Molecular Medicine Research Institute, Sunnyvale, CA
Background/Purpose: Rheumatoid arthritis is a chronic systemic autoimmune disease characterized by inflammation and joint destruction; a consequence of which is the high local concentration of…
Abstract Number: 1762 • 2013 ACR/ARHP Annual Meeting
Endogenous IL-22 Regulates Th1 Responses and Plays a Pathogenic Role After the Onset of Arthritis
Shivali Justa¹, Xiaoqun Zhou² and Sujata Sarkar³, ¹Rheumatology & Arizona Arthritis Center, University of Arizona, Tucson, AZ, ²Rheumatology, University of Arizona, Tucson, AZ, ³Rheumatology and Arizona Arthritis Center, University of Arizona, Tucson, AZ
Background/Purpose: IL-22,belongs to the IL-10 family of cytokines and is primarily produced by CD4 T, NK and LTi cells. IL-22 plays a dual role depending…
Abstract Number: 2201 • 2012 ACR/ARHP Annual Meeting
Involvement of Interleukin-33 in the Pathogenesis of Sjögren’s Syndrome
Ahmad Awada, Valérie Gangji and Muhammad S. Soyfoo, Rheumatology, Hôpital Erasme,Université Libre de Bruxelles, Brussels, Belgium
Background/Purpose: To investigate the role of IL-33/ST2 in the pathophysiology of primary Sjögren’s syndrome (pSS) Methods: Serum levels of IL-33 and sST2 was determined by…
Abstract Number: 530 • 2012 ACR/ARHP Annual Meeting
S100A8/A9 Is Upregulated and Triggers the Secretion of Pro-Inflammatory Cytokines in Primary Sjögren’s Syndrome
Laura Weichselbaum¹ and Muhammad S. Soyfoo², ¹Rheumatology, Department of rheumatology ,Hôpital Erasme, Brussels, Belgium, ²Rheumatology, Hôpital Erasme,Université Libre de Bruxelles, Brussels, Belgium
Background/Purpose: To determine the involvement of S100A8/A9 in the pathogenesis of primary Sjögren’s syndrome (pSS) Methods: The serum levels of S100A8/A9, IL-17A and IL-17C were…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].